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ABSTRACT
Acyclic amine-carboxyboranes were effective anti-inflammatory agents in mice at 8 mg/kg x 2.
These amine-carboxyboranes were more effective than the standard indomethacin at 8 mg/kg x
2, pentoxifylline at 50 mg/kg x 2, and phenylbutazone at 50 mg/kg x 2. The heterocyclic amine
derivatives as well as amine-carbamoylboranes, carboalkoxyboranes, and cyanoboranes were
generally less active. However, selected aminomethyl-phosphonate-N-cyanoboranes
demonstrated greater than 60% reduction of induced inflammation. The boron compounds were
also active in the rat induced edema, chronic arthritis, and pleurisy screens, demonstrating
activity similar to the standard indomethacin. The compounds were effective in reducing local
pain and decreased the tail flick reflex to pain. The derivatives which demonstrated good anti-
inflammatory activity were effective inhibitors of hydrolytic lysosomal, and proteolytic enzyme
activities with IC50 values equal to 10"6M in mouse macrophages, human ieukocytes, and Be
Sal osteofibrolytic cells. In these same cell lines, the agents blocked prostaglandin
cyclooxygenase activity with IC50 values of 10"6M. In mouse macrophage and human
leukoces, 5’ lipoxygenase activity was also inhibited by the boron derivatives with IC50 values
of 10"M. These IC50 values for inhibition of these enzyme activities are consistent with
published values of known anti-inflammatory agents which target these enzymes.
INTRODUCTION
Amine-cyanoboranes and amine-carbox, yboranes have previously been shown to inhibit induced
inflammation in rodents at 10 mg/kg . These studies were expanded to include di- and
tripeptides containing boron2, tricyclohexyl- and triphenylphosphine- boranes, carboxyboranes
and cyanoboranes3, and boronated 2-deoxynucleosides4 which demonstrated anti-inflammatory
activity in mice. These boron compounds were potent inhibitors of lysosomal hy.drolytic enzyme
activities and their release from CFl-mouse hepatic tissue and human PMNs1. The current
study extends this investigation to other boron derivatives and additional inflammatory disease
models other than induced edema. Selective derivatives of individual chemical classes of boron
compounds are examined for their mode of action using isolated enzymes and tissue cultured
cells to determine their effects on hydrolytic and proteolytic enzymes and regulatory enzymes of
the prostaglandin and leukotriene synthetic pathways.Vol. 2, No. I, 1995 TheAnti-bammatory Activity ofBoron Derivatives in Rodents
METHODS AND MATERIALS
Source of Materials
All of the boron derivatives have previously been synthesized and the literature references5"24
for each compound are listed in Table 1. The chemical and physical characteristics were
identical to those reported in the literature. Test compounds (1-94) were homogenized in 0.05%
tween 80-distilled/H20.
Anti-inflammatory Activity. CF1 male mice (~25g) were administered test drugs (1-94) at 8
mg/kg/day in 0.05% Tween 80/H20 intraperitoneally at 3 h and again at 30 min prior to the
injection of 0.2 ml of 10% carrageenan in 0.9% saline into the plantar surface of the right hind
foot. Saline was injected into the left hind foot which served as the standard base line. After 3 h,
both feet were excised at the tibiotarsal (ankle) joint according to the modified method of
Winter25,26, resulting in an 84 mg increase in the paw weight of the control mice. Selected
compounds 2, 4, 5, 6, 8, 9, 11, 12, 15, 16, 23, 33, 34, 36, 46, 48, 74, 76, and 78 were tested in
Sprague Dawley male rats (-350 g) at 8 mg/kg x 2, I.P. The average paw weight of the control
rats was increased 1.732 g by the inflammation agent.
Local Analgesic Screen. Male CF1 mice (~25 g) were administered selected test drugs (1-89) at
8 mg/kg, I.P. 20 min prior to the administration of 0.5 ml of 0.6% acetic acid, I.P. After 5 min, the
number of stretches, characterized by repeated contractions of the abdominal musculature,
accompanied by the extension of the hind limbs, were counted for the next 10 min25. The
control mice afforded 61 stretch reflexes per 10 min.
Hot Plate Tail Flick Screen. CF 1 male mice (-28 g) were administered agents at 8 mg/kg, I.P. 15
min prior to placement on a hot plate maintained at 100; The time elapse for the tail to be
raised was determined using a digital read-out connected to ihe hot plate27. Tail flick responses
of mice injected with morphine was used as a standard.
Anti-pleurisy Screen. Sprague Dawley male rats (-280 g) were administered test drugs 2, 8, 9,
12, 15, 16, 20, 34, or 76 at 8 mg/kg I.P., 1 h before and 3 h after injecting into the pleural cavity
0.05 mi of a 0.316% Evan’s blue and carrageenan28. Six hours later, the rats were sacrificed
and the fluid collected from the pleural cavity. Control rats produced an average of 2.15 ml of
fluid.
Chronic Adjuvant Arthritic Screen. Male Sprague Dawley rats (-180 g) were injected at the base
of the tail with 0.2 ml of solution containing 100 mg of dried M._=. but.yricum and 40 mg digitonin in
20 ml of light mineral oil29. Test drugs 2, 7, 8, 12, 20, 34, or 78 were administered on Day 3 to
Day 21 at 8 mg/kg/day, I.P. The following day, the rats were sacrificed and the feet were excised
and weighed. Control rats averaged a 0.750 g net weight increase.
Cell Maintenance of Cultured Cells. Mouse macrophages J774A were maintained in Dulbecco’s
modified Eagle medium (DMEM) + 15% FCS + P/S. RMPI 1788 human leukocytes were
maintained in RMPI 1640 + 10% FCS + P/S. Be Sal human osteo-fibrolytic cells were
maintained in RMPI + 10% FCS + P/S. Rat osteogenic sarcoma cells UMR-106 were maintained
in DMEM + 10% FCS + P/S.
Lysosomal Hydrolytic Enzymatic Activities. Acid phosphatase, aryl sulphatase, cathepsin, and
trypsin proteolytic activities were measured utilizing human Be Sal osteo-fibrolytic osteoporosi_s
cells, leukocytes, or mouse macrophages J774 (1 x 106 cells). Drugs were incubated from 10" to 10-3 M for 30 min at 37C. Acid phosphatase activity was determined using 0.1 M I]-
glycerolphosphate in 0.1 M acetate buffer at pH 5.032. The reaction was stopped with 10% TCA
and centrifuged at 3000 g x 6 mino The suernatant inorganic phosphate was determined by the
spectrophotometric method of Chen et. al.30. The net inorganic phosphate released in 30 minLH. Hall, B.S. Burnham, S. Y. Chen, A. Sood, B.F. Spielvogel and K. W. Morse Metal BasedDrugs
was corrected by subtracting the blank test. Aryl sulphatase activity was measured using 0.72
mmole of p-nitrocatechol sulfate as a substrate in 0.2 M acetate buffer, pH 5.0 for 30 min at 37
C31. The reaction was terminated with 4N NaOH. The formation of 4-nitrocatechol in the
supernatant was measured spectrophotometricaily at 510 nm and corrected for blank values.
Cathepsin activity was determined using 2% azocasien as the substrate in 0.1 M acetate buffer,
pH 5.0 for 30 min at 37C31. The reaction was terminated with 10% TCA and centrifuged. The
supernatant was assayed for acid-soluble peptide fragments at 366 nm and corrected for blank
values.
Proteolytic Enzyme Activities. Trypsin proteolytic activity was determined by the method of
Schleuning and Fritz33 using 2.0 ml of 0.1 M Tris buffer, pH 8.0 and 6 mM of N-benzoyI-L-
arginine ethyl ester (BAEE) substrate. The hydrolysis of BAEE over a 30 min period was
determined at 253 nm and blank values were subtracted33. Elastase activity was determined by
the method of Kleinerman et al.34 using 2.9 ml of 0.2 M Tris-HCI buffer, pH 8.0, 2 units (200 i1)
of porcine pancreatic elastase (Sigma, Type III) and 20 I1 N-succinyI-L-alanyI-L-alanine-p-
nitroanilide (Sigma, 100 mg in 5 ml of methyl-2-pyrrolidone). The cleaved product p-nitroanilide
was determined at 410 nm for a 3 min period. Collagenase activity was determined at 410 nm
for a 3 min period. Collagenase activity was determined by the method of Hu et al.35 using 1 ml
of 50 mM Tris + 5 mM CaCI2 buffer, pH 7.6, 10 Ig 3H-collagen N-(propionate 2,3-
3H)propionylated (0.51 mCi/mg) and 10 Ig collagenase (Sigma, Type III Clostridium
histolvticum)36 incubated for 24 h at 37C. The reaction was stopped with 1 ml 50 mM EDTA.
The tubes were then centrifuged at 10,000 g for 15 min. The supernatant was counted (Packard
Tricarb liquid scintillation counter). Background radioactivity values were subtracted from each
sample and corrected for quenching.
Prostaglandin Synthetase Activity. The incubation medium of Tomlinson et al.37 was used to
determine prostaglandin formation et al. from 3H(N)-arachidonic acid (100 Ci/mmole) and 10 mg
of purified commercial prostaglandin synthetase from bovine seminal vesicles (Miles Research
Products) or 106 J774 macrophage cells. After 1 h, the reaction was terminated with 2N HCI and
the mixture was extracted with ether and evaporated. The residue was dissolved in ethyl acetate
and spotted on silica gel TLC plates which were eluted with chloroform, methanol, water, and
acetic acid (90:8:1:0.8). The plates were developed in iodine vapor and the area appropriate to
prostaglandin standards was scraped and counted38, i.e. arachidonic acid, PgA2, PgE2, and
PgF2. The dpm in each area was calculated as percent of the total dpm on the tic plate.
5’Lipoxygenase Activity. Mouse macrophages or human leukocytes (5 x 106 cells) were
maintained as described above and then incubated at 10-4 to 10-8 M. The cells were harvested
by centrifugation and incubated in a phosphate buffer, pH 7.2, + 0.6 mM CaCI2 + 1.0 mM MgCI2,
the calcium ionophore A 23187, and 3H-arachidonic acid. After 20 min incubation at 37C,
EtOAc:CH2CI2 (2:3) supplemented with 12 mg arachidonic acid was added. The organic phase
was extracted and dried. The residue was taken up in ethyl acetate and 100 pL was plated on
silica gel TLC plates eluted with methylene chloride:methanol:acetic acid: water (90:8:1:0.8).
The plates were scaped in the area that corresponded to 5-HETE and counted39"40. The IC50
values were calculated for the compounds.
In Table 1, the anti-inflammatory activity is represented as percentage of control and the
standard deviation (X :1: S.D.). N equals the number of animals used in each test group. IC50
values were calculated as the dose (log) which afforded 50% inhibition of the enzyme activity +
S.D. The P values were determined using the Student’s "t" test and analysis of variance.Vol. 2, No. 1, 1995 The Anti-Inflammatory Activity ofBoron Derivatives in Rodents
RESULTS
In the mouse edema screen, compounds. 15, 16, and 19, the methyl and ethyl ester derivatives
of amine-carboxyboranes 13-20 were less active than the simple acids (Table 1). The amides
21-31, except compound 23, were also less active than the acids. The ammonia di- and
trimethylamine cyanoboranes 32-34 demonstrated good activity as did the C18H37 derivative 36
and the dicyano derivative 40. Nevertheless, the remaining cyanoboranes demonstrated
minimum activity. The phosphonoacetate analogs and aminoalkylphosphonate derivatives
demonstrated good activity where compounds 54, 62, 64, 66, 67, 68, 69, 71, 73, 74, 75, and 76
caused at least 40% reduction of induced edema in mice at 8 mg/kg x 2. The heterocyclic amine
boranes derivatives 78-94 were not as active as other boron containing derivatives. Compound
78 caused 45% reduction of induced edema. Compounds 83, 84, 87, and 91 resulted in at least
30% reduction of inflammation in mice.
Compounds 4, 5, 6, 8, 15, and 23 demonstrated at least 40% reduction in induced edema in rats
at 8 mg/kg x 2 (Table 2). Chronic arthritis in rats was reduced significantly by 7, 20, and 34 with
greater than 75% reduction of pannus at 8 mg/kg/day. Compounds 2, 8, 12, and 78 were
significantly active in this screen. Pleurisy edema in rats was reduced significantly by
compounds 2, 8, 9, 12, 16, 20, 34, and 76. Selective agents were able to block local pain
induced by acetic acid in mice. Compounds 1, 4, 5, 8, 9, 12, 15, 16, 33, 34, 35, and 78 reduced
the reflex action by 80%. Compounds 2, 7, 20, 23, 27, 36, 46, 48, 74, 75, 76, and 77 caused at
least 45% reduction of the reflex action. The tail flick assay time was increased by compounds 2,
3, 5, 8, 9, 12, 15, 16, 46, 75, and 76; however, only compounds 9, 75, and 76 were as effective
as morphine in blocking central pain.
Lysosomal enzyme activity, e.g. acid phosphatase, cathepsin, and aryl sulfatase activities (Table
3) were inhibited by the boron derivatives. Acid p_hosphatase activity in mouse macrophages
demonstrated IC50 values between 0.90-7.72 x 10"6M for the boron derivatives tested, for acid
cathepsin activity values between 0.76-9.45 x 10"6M, and for aryl sulfatase activity values
between 1.37-9.71 10"6M, except for compound 14 (17.6 x 10"6M)._ Human Be Sal cells showed
IC50 values for acid phosphatase activity between 1.10-18.3 x 10"6M, for acid cathepsin activity
values between 0.85-6.17 x 10"6M, and for aryl sulfatase activity values between 6.07-10.00 x
10"6M. For human leuko_cytes acid phosphatase activity, the IC50 values (Table 4) were
between 8.57-10.49 x 10"6M, and acid cathepsin activity values between 5.38-7.71 x 10"6M.
Proteolytic enzyme activities were also reduced by the boron derivatives. Ma_crophage trypsin
activity (Table 5) was inhibited with IC50 values between 1.26-4.34 x 10"6M, macrophage
elastase activity was inhibited with IC50 values ranging from 0.22-9.01 x 10"6M. Be Sal trypsin
activity demonstrated inhibition with IC50 values between 3.35-7.40 x 10"6M able 4) whereas
elastase activity was inhibited with IC50 values in the range of 0.58-3.86 x 10"6M. Macropha_ge
trypsin and elastase activities were inhibited by the compounds with IC50 values 10"6M.
Commercial collagenase activity was inhibited with IC50 values between 615-812 x 10"6M
(Table 5) and type II activity with IC50 values between 89-124 x 10"6M. Human bone osteoge_nic
sarcoma cells (Table 6) trypsin activity was inhibited with IC50 values of 5.67-10.51 x 10"6M,
elastase activity values of 8.09-10.34 x 10"6M, and acid cathepsin activity values between 467-
6.62 x 10"6M. Beef seminal vesicle prostaglandin cyclooxygenase activit (Table 7) was
inhibited by the boron derivatives with IC50 values ranging from 0.71-7.60 x 10-M. Macrophage
prostaglandin cyclooxygenase activity IC50 values were between 1.47-7.72 x 10"6M, and Be Sal
cells showed IC50 values between 1.09-8.04 x 10-6M. Human leukocyte 5’-Iipo_xygenase activity
was inhibited by the boron derivatives with IC50 values between 3.47-6.43 x 10"6M.LH. Hail B.S. Burnham, S. Y. Chen, A. Sood, B.F. Spielvogel and K. W. Morse Metal BasedDrugs
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Table 2. The i.Bn vivo Antiinflammatory and Analgesic Activities of Boron Derivativesin
Rats and Mice at $ mglkg (% of control)
Rat Mice
Chronic Writhing Tail
Compound, Inflammatory Arthritis Pleurisy Reflex Flick
1 19
2 70 53 61 31 147
3 156
4 55 2
5 59 1 196
6 55 19
7 24 55
8 59 40 19 16 167
9 72 37 14 231
11 77
12 61 49 28 19 197
15 59 86 12 147
16 71 45 2 180
20 13 61 36
23 41 27 81
25 89
30 34
33 61 15
34 65 4 65 18
35 16
36 74 61
46 46 191
48 78 50 134
74 81 40
75 34 279
76 60 50 45 258
77 41 139
78 83 33 15
$7 89
Indomethacin 78 55 12 43
Morphine 213
Phenylbutazone 47
Discussion
The amine-carboxyboranes and related derivatives were not all active as anti-inflammatory
agents in rodents at 8 mg/kg x 2. Nevertheless, selected compounds were equally active as the
clinically used standards indomethacin, phenylbutazone, and pentoxifylline which afforded 26,
47, and 30% inhibition, respectively of induced inflammation at their therapeutic dose. A number
of the amine-carboxyboranes and cyanoborane derivatives were more potent in reducing edema
at 8 mg/kg x 2. The mode of actions of the active compounds appears to be similar to those
previously reported for cyanoboranesI in that these agents effectively reduced the activities of
lysosomal and proteolytic enzymes in a number of cultured cells. Particularly important is their
inhibition on these processes in macrophages, leukocytes, and Be Sal osteo-fibrolytic cells.
Studies have recently shown that the carboxyborane derivatives effectively inhibit the release of
chemical mediators, e.g. tumor necrosis factor-alpha, I1-1 and 11-2 from macrophages and further,VoL 2, No. 1, 1995 The Anti-InflammatoryActivity ofBoron Derivatives in Rodents
these same agents reduce the movement of PMNs and macrophages to sites of inflammation41.
These chemical mediators, when released from inflammation cells, interact with high affinity
receptors of target cells causing release of hydrolytic and proteolytic enzymes which cause local
destruction of the tissue. Released locally also are prostaglandins and leukotrienes which afford
additional inflammation, edema, pain, and destruction of tissue. Apparently, the boron
derivatives are potent inhibitors of both prostaglandin cycooxygenase and 5’-Iipoxygenase
activities of human leukocytes and mouse macrophages with IC50 values which are typical of
anti-inflammatory agents, i.e. 10"6M. The fact that these agents are dual inhibitors is most
significant since all agents are not able to achieve this function. The inhibition of 5’-Iipoxygenase
activity by the amine-carboxyboranes is potent achieving an order of magnitude greater inhibition
than most dual inhibitors under investigation41,42. The amine-carboxyboranes, like most anti-
inflammatory agents, function by multiple modes of action to reduce inflammation and pain.
Table 3. IC50 Values X 10-6M For Inhibition of Lysosomal Enzymes
Mouse
Macrohaqe
Acid Aryl
Compound # Phosphatase Cathepsin Sulfatase
1 8.08 4.62
2 0.90 9.45 8.30
3 4.75 6.39
7 3.32 8.37
8 0.94 7.18 9.71
9 5.34 5.09
11
12 1.08 5.52 8.58
15 1.04 6.71 7.41
16 3.55 8.28 17.60
20 1.12 3.94 9.27
23 1.12 3.95 9.27
33 1.13 5.54 9.02
:34 1.05 6.34 9.29
35 0.33 4.97 7.16
36 2.68 3.69
40 1.10 6.89 8.48
46 7.72 2.57 3.40
57 4.43 6.49
59 2.04 6.55
74 1.31 9.13 6.03
75 6.61 4.58 1.50
76 3.96 1.69 1.37
77 6.59 5.13 1.40
78 3.18 0.76
83 0.16 1.76 7.59
87 2.68 3.99
95 3.24 9.24
Human
..B .e.. Sal Osteofibrolytic
Acid Aryl
Phoshatase Cathepsin Sulfatase
10.20 4.28 9.14
1.77 8.86
2.06 1.37 6.07
18.30 5.44 8.16
15.30 4.28 9.33
1.10 8.59
8.60
8.70
15.90
2.01
10.30
0.73
1.28
1.93
0.85
1.34
10.00
7.62
7.63
7.91
8.87
6.17 8.80
4.40
2.93
8.99
8.99LH. Hall B.S. Burnham, S. Y. Chen, A. Sood, B.F. Spielvogel and K. W. Morse Metal BasedDrugs
Table 4. IC50 Values X 10-6 M For Inhibition of Human Enzyme Activities
,,Compound #
1
2
8
12
15
16
20
23
33
34
35
36
40
74
76
78
83
Be Sal Osteofibrolic
Trypsin Elastase
7.00 3.15
7.04 1.39
7.40 3.86
5.70 1.96
6.14 1.31
4.36 1.97
4.36 0.98
6.43 3.36
3.98 3.29
5.87 1.65
3.35 1.21
4.47 2.12
3.35 3.60
7.88 1.84
7.88 0.575
Acid PhosDhatase
7.25
9.94
10.80
10.49
10.03
8.57
6.52
9.69
8.58
,L.eu,kocytes
Cathpsin
7.03
6.46
11.00
5.97
9.77
5.38
7.71
10.62
7.28
Trypsin
8.50
6.72
11.31
9.95
7.25
9.68
7.40
Table 5. Proteolytic Activity IC50 Values x 10-6M for Boron Derivatives
Mouse Macrophafle
.Compound # Trypsin Elastase
1 2.09 0.22
2 2.34 2.32
3 3.10 2.67
7 2.33 2.76
8 1.26 1.80
9 2.07 6.29
12 1.77 3.04
15 2.78 2.14
16 3.23 8.76
20 2.02 3.28
23 2.03 3.29
33 2.44 2.53
34 1.41 1.35
35 2.69 2.75
36 4.34 10.30
40 1.63 2.02
46 2.40 5.21
57 3.76 9.01
59 4.46 8.27
74 1.83 2.32
75 2.51 7.59
76 2.06 4.83
77 2.14 1.49
78 2.39 5.94
83 2.37 0.96
87 2.85 6.98
95 2.62 6.17
..Clostridium histolyticum
,Co!lagenasel C011agenase II
101
90
667
615 109
663
107
797 124
106
113
617
110
101
643
687
783
812
97
89
99
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Table 6. Rat UMR-10$ Bone Osteosarcoma IC50 Values X 10-6M
Neutral
,,Compound Trypsin Cathepsin Elastase
1 7.74 4.67 9.26
2 9.89 5.82 8.94
8 6.56 6.59 9.58
12 5.67 5.81 8.86
15 6.57 6.10 9.74
20 9.18 6.62 10.34
33 7.54 6.24 9.04
34 2.62 5.46 8.99
35 7.28 6.31 9.19
40 9.48 6.54 9.96
74 10.51 6.55 10.02
$3 9.89 5.41 8.09
Table 7. The Effects of Amine-carboxyboranes on Prostaglandin Cyclooxygenase and 5’-
Lipoxygenase Activities IC50 Values X 10-6 M
Compound #
Prostaqlandin Cyclo0xygenase 5’-!,ipoxy_qenase
Beef
Be Sal Seminal Mouse Human
Macrophages Osteofbro Vesicle Macrophage Leukocytes
1 4.19 3.94
2 3.50 7.48 1.15
3 2.91 3.26 5.83
7 1.85
8 2.55 6.77 2.43 8.76 1.53
9 2.51 1.92
12 3.53 5.49 7.60 9.80 4.77
15 2.81 4.24 2.86 6.61 5.37
16 2.41 2.98 5.37
23 5.19 8.05 6.59 2.80
33 5.92 5.58 9.89 3.47
34 5.88 4.26 5.90 8.07 6.43
36 2.23 6.67 5.67
40 3.05 9.29 8.80 3.28
46 6.59 2.33 0.71 6.39
57 3.09
74 1.52 6.31 4.06
75 6.61 3.68 4.31
76 1.61 1.30
77 7.72 1.09 1.39
78 1.47 3.41 2.37
95 2.20
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